Xagrid 0.5mg hard capsule

  • Name:

    Xagrid 0.5mg hard capsule

  • Company:
    info
  • Active Ingredients:

    Anagrelide hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/09/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 6/9/2019

Click on this link to Download PDF directly

Shire Pharmaceuticals Ireland Limited

Shire Pharmaceuticals Ireland Limited

Address: Shire Pharmaceuticals Ireland Limited, Block 2, Miesian Plaza, 50-58 Baggot St, Dublin 2, Ireland

Medical Information E-mail: medinfoEMEA@shire.com

Customer Care direct line: 01800837470

Company Products

Medicine NameActive Ingredients
Medicine Name Buccolam 2.5mg, 5mg, 7.5mg and 10mg oromucosal solution Active Ingredients Midazolam Hydrochloride
Medicine Name Cinryze 500 IU powder and solvent for solution for injection Active Ingredients C1 inhibitor (human)
Medicine Name Equasym XL 10, 20 & 30mg Modified Release Capsules Active Ingredients Methylphenidate Hydrochloride
Medicine Name Firazyr 30 mg solution for injection in pre-filled syringe Active Ingredients Icatibant Acetate
Medicine Name Foznol 250mg, 500mg, 750mg & 1000mg Chewable Tablets Active Ingredients Lanthanum Carbonate Hydrate
Medicine Name Intuniv 1mg, 2mg, 3mg, 4mg prolonged-release tablets Active Ingredients Guanfacine hydrochloride
Medicine Name Mezavant XL Active Ingredients Mesalazine
Medicine Name Reminyl Oral Solution Active Ingredients Galantamine Hydrobromide
Medicine Name Reminyl XL 8mg, 16mg and 24 mg prolonged release capsules Active Ingredients Galantamine Hydrobromide
Medicine Name Resolor 1 mg film-coated tablets Active Ingredients Prucalopride Succinate
Medicine Name Resolor 2 mg film-coated tablets Active Ingredients Prucalopride Succinate
Medicine Name Tyvense 20mg, 30mg, 40mg, 50mg. 60mg & 70mg Capsules, hard Active Ingredients Lisdexamfetamine dimesylate
Medicine Name Tyvense 20mg, 40mg & 60mg Capsules, hard Active Ingredients Lisdexamfetamine dimesylate
Medicine Name Xagrid 0.5mg hard capsule Active Ingredients Anagrelide hydrochloride
1 - 0 of 14 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 September 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 6 September 2019 SmPC

Reasons for updating

  • Change to section 9 - Date of first authorisation/renewal of the authorisation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 9, update to the renewal date.

Updated on 5 November 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to other sources of information section
  • Company name change or merger

Updated on 31 October 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to other sources of information section
  • Company name change or merger

Updated on 31 October 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text
  • Company name change or merger

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 7 (Marketing authorisation holder), MAH name and address change to 'Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, Ireland'

Updated on 22 May 2018 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 22 May 2018 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 18 May 2018 PIL

Reasons for updating

  • Removal of Black Inverted Triangle

Updated on 5 September 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 5 September 2017 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 7 the MAH address has been changed from Shire Pharmaceutical Contracts Limited, Hampshire International Business Park, Basingstoke, Hampshire, RG24 8EP, UK to Shire Pharmaceuticals Contracts Limited, One Kingdom Street, London W2 6BD, UK

Updated on 17 August 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 17 August 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 14 July 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4 (special warnings and precautions for use) - addition of Pulmonary hypertension

4.8 (undesirable effects) - re-classification of ‘Pulmonary Hypertension’ from “rare” to “uncommon”

Updated on 10 July 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 17 May 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4:

Platelets

The platelet count will increase within 4 days of stopping treatment with anagrelide and will return to pre-treatment levels within 10 to 14 days, possibly rebounding above baseline values. Therefore platelets should be monitored frequently..

Section 4.5

Effects of other active substances on anagrelide

·               In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide. 

CYP1A2 inhibitors

·               Anagrelide is primarily metabolised by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine and enoxacin, and such medicinal products could theoretically adversely influence the clearance of anagrelide.

·                  In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide.

CYP1A2 inducers

·         CYP1A2 inducers (such as omeprazole) could decrease the exposure of anagrelide increasing its main active metabolite. The consequences on the safety and efficacy profile of anagrelide are not established. Therefore, clinical and biological monitoring is recommended in patients taking concomitant CYP1A2 inducers. If needed, anagrelide dose adjustment could be made.

Section 5.1

Mechanism of action

The precisespecific mechanism of action by which anagrelide reduces blood platelet count is  not yet fully understood although it has been confirmed that anagrelide is platelet selective from in vitro and in vivo study informationunknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

 and a corresponding update to Section 10

Updated on 15 May 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 7 December 2015 PIL

Reasons for updating

  • Change to date of revision

Updated on 7 May 2015 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



Update of section 4.6 of the SmPC with new information regarding breast-feeding and fertility.
Update of section 5.3 of the SmPC based on new non-clinical data.
Update of section 10. Date of revision of the text to April 2015.
In addition, Shire took the opportunity to make editorial changes in the SmPC and to update the contact details of the local representatives in the Package Leaflet.

Updated on 1 May 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 24 November 2014 SmPC

Reasons for updating

  • Change to paediatric information
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following sections have been updated to include new information on use in the paediatric population in line with the completed Paediatric Investigation Plan (PIP).  See the relevant ‘Paediatric population’ sub-section under  -  

 

4.2 Posology and method of administration

4.4 Special warnings and precautions for use

4.8 Undesirable effects

5.1 Pharmacodynamic properties

5.2 Pharmacokinetic properties

 

Other

 

4.4 Special warnings and precautions for use – update regarding monitoring for evidence of cardiovascular effects.

 

Minor text updates in line with the latest version of the Quality Review Document (QRD) template throughout the SmPC.

 

Updated on 24 November 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 31 July 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 has been updated with the following statement:
Use of concomitant anagrelide and acetylsalicylic acid has been associated with major haemorrhagic events (see section 4.5).

Section 5.2 has been updated with the appropriate QRD sub-headings.

Updated on 4 February 2014 PIL

Reasons for updating

  • Change of manufacturer

Updated on 4 December 2013 SmPC

Reasons for updating

  • Addition of black triangle
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In line with QRD9 addition of Black Triangle and associated text.
In section 4.2 (Posology and method of administration) and 5.2 (Pharmacokinetic properties), QRD9 template update to wording re the elderly.
In section 4.4 (Special warnings and precautions for use), updates to Monitoring and Cardiovascular subsections following the results of a thorough QT/QTc study.
In section 4.5 (Interactions), reference to omeprozole replaced with enoxacin.
In section 4.8 (Undesirable effects) addition of torsade de pointes, in line with updates in section 4.4. QRD9 updates regarding reporting of suspected adverse events.
In Section 5.1 (Pharmacodynamic properties), new section added as result of the QT/QTc study.

Updated on 2 December 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of black triangle

Updated on 4 June 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 3 June 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

QRD 8.2 amendments as follows:
In section 2, Excipients header changed to Excipient(s) with known effect.
In section 4.3 crossreference to section 6.1 added
In section 5.1, 'm' added to SmPC
In section 9 - reference to month changed from numbers to letters ie November
In section 10 - revision date amended.

Updated on 23 January 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company


  • Changes to SmPC:
  • QRD version 8 template changes.
  • Section 4.2 (Posology and method of administration), Paediatric population, Renal and Hepatic impairment sections re-worded.
  • Section 4.4 (Special warnings and precautions for use, cardiovascular), updated with serious cardiac side effects added from section 4.8 Please notification form for more details.
  • Section 4.5 (Interaction with other medicinal products and other forms of interaction), paediatric population added to this section.
  • Section 4.6 (Fertility, pregnancy and lactation), section re-worded.
  • Section 4.8 (Undesirable effects), section reformatted and two new terms added to Respiratory SOC “Pneumonitis and Interstitial Lung Disease”, these are used in addition/interchangeably to allergic alveolitis.
  • Section 4.9 (Overdose), has been re-ordered.

Updated on 22 January 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to further information section
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 6 June 2011 PIL

Reasons for updating

  • Change to further information section

Updated on 18 May 2011 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.5 …..

 

Drug interactions: effects of anagrelide on other substances

·               Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other co-administered medicinal products sharing that clearance mechanism e.g. theophylline.

·               Anagrelide is an inhibitor of PDE III. The effects of medicinal products with similar properties such as the inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.

·               In vivo interaction studies in humans have demonstrated that anagrelide does not affect the pharmacokinetic properties of digoxin or warfarin.

·               At the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may theoretically potentiate the effects of other medicinal products that inhibit or modify platelet function e.g. acetylsalicylic acid.

·               A clinical interaction study performed in healthy subjects showed that co-administration of repeat-dose anagrelide 1 mg once daily and acetylsalicylic acid 75 mg once daily may enhance the anti-platelet aggregation effects of each drug compared with administration of acetylsalicylic acid alone. In some ET patients concomitantly treated by acetylsalicylic acid and anagrelide, major haemorrhages occurred. Therefore, due to the lack of data in ET patients, the potential risks of the concomitant use of anagrelide with acetylsalicylic acid should be assessed, particularly in patients with a high risk profile for haemorrhage before treatment is initiated.

·               Anagrelide may cause intestinal disturbance in some patients and compromise the absorption of hormonal oral contraceptives.

Food interactions

·               Food delays the absorption of anagrelide, but does not significantly alter systemic exposure.

·The effects of food on bioavailability are not considered clinically relevant to the use of anagrelide.

...........

 

Updated on 17 May 2011 PIL

Reasons for updating

  • Change to drug interactions

Updated on 28 February 2011 PIL

Reasons for updating

  • Change to MA holder contact details
  • Change to name of manufacturer
  • Correction of spelling/typing errors

Updated on 8 December 2010 PIL

Reasons for updating

  • Change to side-effects
  • Change of distributor details
  • Correction of spelling/typing errors

Updated on 7 December 2010 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects: was amended to add ' Tubulointerstitial nephritis' to the subsection, 'Renal and urinary disorders'. The incidence rate is not known.

Section 10 Date of Revision of the Text: was amended to reflect the approval date of 11/10.

Updated on 27 May 2010 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



4.4        Special warnings and special precautions for use

 

...

 

GeneralMonitoring

Therapy requires close clinical supervision of the patient which will include a full blood count (haemoglobin and white blood cell and platelet counts), and assessment of liver function (ALT and AST) and renal function (serum creatinine and urea) tests.

...

4.8    Undesirable effects

 

Hepatobiliary disorders

Uncommon:      Hepatic enzymes increased

Not known:       Hepatitis




10. DATE OF REVISION OF THE TEXT

 

04/201005/2010

 

 

Updated on 25 May 2010 PIL

Reasons for updating

  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 11 May 2010 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 6.3, the shelf-life has been changed from 3 to 4 years.

Updated on 19 January 2010 PIL

Reasons for updating

  • Change to date of revision
  • Change of distributor details

Updated on 1 December 2009 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4 - Clinical particulars
  • Change to section 5 - Pharmacological properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Renewal. EC Decision 30-Oct-2009. Administrative updates to Annex I (SmPC) and Annex III (Labelling and Package Leaflet) in line with comments from QRD during renewal assessment.

Updated on 10 November 2009 PIL

Reasons for updating

  • Change of contraindications
  • Change to side-effects
  • Change to information about driving or using machinery
  • Change to date of revision
  • Change to dosage and administration
  • Change to MA holder contact details
  • Correction of spelling/typing errors

Updated on 9 March 2009 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to MA holder contact details

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Due to clinical trial publication, interactions with aspirin updated. Also new address details for contacts.

Updated on 6 March 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Addition of marketing authorisation holder
  • Change to drug interactions

Updated on 10 December 2008 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2
Elderly
 
Delete: No specific pharmacokinetic studies have been conducted in this patient population.
Add: The observed pharmacokinetic differences between elderly and young patients with ET (see section5.2) do not warrant using a different starting regimen or different dose titration step to achieve an individual patient-optimised anagrelide regimen.
 
Section 5.2
Add
Elderly: Pharmacokinetic data from fasting elderly patients with ET (age range 65-75 years) compared tofasting adult patients (age range 22-50 years) indicate that the Cmax and AUC of anagrelide were 36% and 61% higher respectively in elderly patients, but that the Cmax and AUC of the active metabolite, 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline, were 42% and 37% lower respectively in the elderly patients. These differences were likely to be caused by lower presystemic metabolism of anagrelide to 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline in the elderly patients.
 

Updated on 10 December 2008 PIL

Reasons for updating

  • Change to further information section

Updated on 1 October 2008 PIL

Reasons for updating

  • Change to further information section

Updated on 20 February 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 18 February 2008 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2 Posology and method of administration:  QRD statement re use in children and adolescents added.
Section 5.1 Pharmacodynamic properties:  Full ATC code included
Section 5.3 Preclinical safety data:  Mutagenic and carcinogenic potential section updated with the findings from a 2 year carcinogenicity study.

Updated on 7 June 2007 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 2 April 2007 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Correction of spelling/typing errors
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4:  Addition of lactose warning statement
Section 4.8:  Addition of 'allergic alveolitis'
Minor typographical/spelling corrections throughout text
Section 10:  Date of revision updated to 28 March 2007

Updated on 22 November 2006 PIL

Reasons for updating

  • Change of contraindications
  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 16 August 2006 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2:  Posology and method of administration:  deletion of last two sentences under the Renal Impairment subheading concerning dose titration and administration to patients with mild to severe renal impairment
 
Section 4.8:   Undesirable effects:  Addition of 'pulmonary hypertension' and 'hepatic enzymes increased'.  Correction to placing of 'migraine' so that it is under 'Nervous system disorders'
 
Section 4.9:  Update to overdose statement
 
Section 5.1:  Deletion of 'Proposed' in relation to ATC code

Updated on 9 March 2006 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 9 March 2006 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 25 November 2005 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 29 September 2005 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 1 July 2005 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 March 2005 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)